

# BIOTECH Therapy



## WAVEIMMUNE

Technology matured by



#Immunotherapy

#Colorectal carcinoma

#PD-L1 inhibitors

Anti-PD-1/PD-L1 immunotherapy has become a major strategy in the fight against cancer with the aim of reprogramming or activating anti-tumor immunity to kill tumor cells without damaging normal cells.

**WAVEIMMUNE** compounds are small molecules, PD-L1 inhibitors with solid *in vitro* and *in vivo* results :

- AliPD1 is the lead of the series
- *In vitro* target engagement
- *In vivo* significant reduction in tumor volume in a colorectal carcinoma

### IP status

PCT,

Priority date : June 30th 2024


### On going :

*In vivo* PoC on other models

MoA studies

Novel inhibitors of the immuncheckpoint PD-L1 for the treatment of a wide spectrum of cancers.

- Lead compound administered as oral drug



ATE : Atezolizumab

CONTACT SATT Nord

Bruna GIOIA | Business Developer | [bruna.gioia@sattnord.fr](mailto:bruna.gioia@sattnord.fr)



Région  
Hauts-de-France



Cofinancé par  
l'Union européenne